Held September 22–23 in San Francisco, CA; the Summit will convene healthcare investors, industry leaders, and innovators to discuss the latest investment strategies and advances shaping the healthcare landscape
Lawrenceville, NJ, USA—July 20, 2026—ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.
In today's healthcare market, scientific innovation alone no longer determines investment success. Increasingly, evidence of value, reimbursement, and policy are shaping which therapies attract capital and ultimately reach patients. According to Deloitte, in 2025, investors shifted capital toward companies with stronger clinical evidence and clearer commercialization pathways, with approximately 80% of venture investment supporting Phase I and II assets that demonstrated stronger potential for commercial success.
The ISPOR Healthcare Investment Summit 2026 is designed to provide investors and industry leaders with insights into how healthcare products are evaluated, reimbursed, and adopted in today's rapidly changing policy environment. Through expert-led sessions and interactive discussions, attendees will explore the evolving relationship between scientific innovation, market access, and investment strategy.
The Summit will open with a keynote address from George Scangos, PhD of ARCH Venture Partners, former CEO of Biogen and Vir Biotechnology, who will speak to how biotech executives and investors can thrive in the upcoming next biotech cycle. Sessions will focus on a variety of topics key to healthcare investors including, the health economic playbook for builders and backers, how HEOR can offer a strategic advantage for development-stage companies, drug pricing policy, creative financing models for gene therapies, patient insight as a strategic advantage, and reducing the cost of evidence generation.
“As policy, pricing, and reimbursement continue to evolve, investors and healthcare innovators need a more robust understanding of the factors that determine whether a therapy reaches patients and succeeds in the marketplace. This is why ISPOR is deliberately engaging with the investor and innovator community – it represents a new and important frontier for our Society,” says ISPOR CEO Rob Abbott.
Additional information can be found at:
Register Here | Summit Website | Program | HEOR Explained
###
ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website | LinkedIn | X (@ispororg) | Bluesky | YouTube | Facebook | Instagram